AstraZeneca Inks a Pact with CSPC Pharmaceutical Group to Advance a Lipid-Lowering Pre-Clinical Candidate
Shots:
- AZ has signed an exclusive licensing agreement with CSPC Pharmaceutical Group to develop a novel small molecule disruptor of Lipoprotein (a) for treating dyslipidaemia & bolstering its cardiovascular portfolio
- As per the agreement, AZ will develop YS2302018 as monotx. or in addition to AZD0780 (oral small molecule PCSK9 inhibitor) for addressing wide range of cardiovascular disease indications
- CSPC is entitled to get $100M upfront plus ~$1.92B development & commercialization milestones as well as tiered royalties
Ref: Astrazeneca | Image: Astrazeneca
Related News:- AstraZeneca Reports the Data from P-IIIb (BATURA) Study of Airsupra (Albuterol/Budesonide) for Intermittent or Mild Persistent Asthma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
